Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The U.S. Food and Drug Administration has filed for dismissal of Mylan's March 18 motion that sought a declaratory judgement to enforce provisions of the Application Integrity Policy against Ranbaxy, calling for an immediate denial of the ANDA for Pfizer's leading cholesterol-lowering agent Lipitor (atorvastatin) to the Indian company

You may also be interested in...



Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity

Questions during an April 28 court hearing suggest Mylan Pharmaceuticals Inc. may have a difficult time persuading a federal judge that it has standing, at this time, to force an FDA determination on generic marketing exclusivity rights for Pfizer's Lipitor

Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity

Questions during an April 28 court hearing suggest Mylan Pharmaceuticals Inc. may have a difficult time persuading a federal judge that it has standing, at this time, to force an FDA determination on generic marketing exclusivity rights for Pfizer's Lipitor

Mylan Sues FDA Alleging Inaction And Failure To Share Clarity On Ranbaxy's Atorvastatin Filings

MUMBAI - Two months after settling a patent litigation with Pfizer Inc. for cholesterol-reducing agent Lipitor (atorvastatin), generic drugs major Mylan Pharmaceuticals Inc. has charged that U.S. FDA's failure to decide and disclose critical information related to Ranbaxy Laboratories' Ltd. abbreviated new drug application for atorvastatin is "unlawful, arbitrary and capricious.

Related Content

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel